Daiichi Sankyo Secures Canadian Reimbursement for Vanflyta in FLT3-ITD AML

Event summary

  • Daiichi Sankyo's Vanflyta (quizartinib) secured public reimbursement in Quebec, Canada, for newly diagnosed FLT3-ITD positive AML patients.
  • The approval follows a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) and Health Canada's Notice of Compliance in June 2025.
  • Vanflyta demonstrated a 22.4% reduction in the risk of death compared to standard chemotherapy in the QuANTUM-First phase 3 trial.
  • The treatment is approved for use across induction, consolidation, and maintenance phases of AML treatment.

The big picture

Daiichi Sankyo's reimbursement deal for Vanflyta addresses a critical unmet need in AML treatment, particularly in the maintenance phase where options have been limited. This approval solidifies Vanflyta's role in the FLT3 inhibitor market and could set a precedent for similar treatments targeting specific genetic mutations in cancer. The strategic move aligns with broader industry trends toward precision oncology and value-based healthcare.

What we're watching

Market Expansion
Whether Daiichi Sankyo can replicate this reimbursement success in other Canadian provinces and international markets.
Clinical Adoption
The pace at which oncologists integrate Vanflyta into standard AML treatment protocols.
Competitive Dynamics
How this approval affects the positioning of Vanflyta against other FLT3 inhibitors in the AML treatment landscape.

Related topics

Oncology